PO Box 9158
Department of Medicine
Section of Dermatology
4th Floor HSCN, Room 4075-A
- BS, Massachussetts Institute of Technology, Cambridge, MA, 1986
- MD, Washington University, St. Louis, MO, 1995
- PhD, Washington University, St. Louis, MO, 1995
Research Papers- Peer Reviewed
1. Eikenberg, J. D., Grider, D. J., & Kolodney, M.S. (2015). Use of Clamping to Enhance lntralesional Bleomycin Therapy for Nodular Basal Cell Carcinoma. JAAD Case Reports, 1(1), 7-8
2. Jayaraman, 55, Rayhan, OJ, Hazany, 5 & Kolodney, MS (2014) Mutational andscape of Basal Cell Carcinomas by Whole-Exome Sequencing. J. Invest Derm. Journal of Investigative Dermatology; 2014 134(1):213-20
3. Thuangtong R, Bentow J, Knopp K, Mahmood NA, David NE, and Kolodney MS (2010) Tissue-selective effects of injected deoxycholate. Dermatologic Surgery 36(6):899-908
4. Nobe K, Hiroko Y, Nobe H, Kolodney MS, Paul RJ, and Honda K (2010) Rho A and the Rho kinase pathway regulate fibroblast contraction enhanced contraction in constitutive active Rho A fibroblast cells. Biochem. Biophys. Res. Commun. 399(2):292-9
5. Bentow JJ, Thuangtong R, Iwasaki J, French SW, and Kolodney MS (2009) A light-emitting mouse to image skin inflammation. Dermatitis 20(3):142-8
6. Oldenburg Rand Kolodney MS (2008) Selective amplification of rare mutations using locked nucleic acid oligonucleotides that competitively inhibit primer binding to wild-type DNA. J. Invest. Dermatol128:398-402
7. Chira Sand Kolodney MS (2007) Skin cancer: Tips on prevention, clues to detection. Consultant 47(6): 589-594
8. lyer S, Carranza D, Kolodney MS, Chipps l, and Soriano T (2007) Evaluation of procollagen I deposition after intense pulsed light treatments at varying parameters in a porcine model. J. Cos. and Laser Ther. 9: 75-78
9. Iqbal M and Kolodney MS (2005) Acne Fulminans with SAPHO syndrome treated with infliximab. J. Amer. Acad. Derm. 52 (5) :S118-20
10. Craft NA, Bruhn KW, Nguyen BD, Prins R, Liau LM, Collisson EA, De A, Kolodney MS, and Gambhir S (2005) Bioluminescent imaging of melanoma in live mice. J. Invest. Dermatol. 125:159-65
11. Rotunda AM and Kolodney MS (2005) Lipomas treated with subcutaneous deoxycholate injections J. Amer. Acad. Derm. 53:973-8
12. Dominguez PL and Kolodney MS (2005) Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens. Oncogene 24(45):6830-4
13. Rotunda AM and Kolodney MS (2005) Mesotherapy and phosphatidylcholine injections: Historical clarification and review. Derm.Surg. 32(4):465-480
14. Rotunda RM, Suzuki H, Moy RL, and Kolodney MS (2004) Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution. Derm. Surg. 30(7):1001-8
15. Collisson EA, Kleer C, Wu M, De A, Gambhir SS, and Kolodney MS (2003) Atorvastatin prevents RhoC isoprenylation, invasion and metastasis in human melanoma cells. Mol. Can. Ther. 2(10):941-8.
16. Collisson EA, De A, Suzuki H, Gambhir SS, and Kolodney MS (2003} Treatment of metastatic melanoma with a small molecule targeted against activating mutations in the BRAF gene. Cancer Res. 63(18}:5669-73
17. Collisson EA, Chen IV, Carranza D, and Kolodney MS (2002} lsoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells. J. Invest. Derm. (2002} 119(5}1172-6
18. Obara K, Nobe K, Nobe H, Kolodney MS, De lanerolle P, and Paul RJ (2000} Effects of microtubules and microfilaments on [Ca(2+}](i} and contractility in a reconstituted fibroblast fiber. Am J Physiol Cell Physiol, 279(3}:C785-96
19. Paul RJ, Bowman P5, and Kolodney M5 (2000} Effects of microtubule disruption on force, velocity, stiffness and [Ca2+] (i} in porcine coronary arteries. Am J Physioi-Heart and Circ. Physiol. 279(5}:H2493-H2501.
20. Wakatsuki T, Kolodney MS, Zahalak Gl, and Elson El (2000} Cell mechanics studied by a reconstituted model tissue. Biophys. J., 79(5}:2353-2368.
21. Kolodney MS, Thimgan M5, Honda HM, Tsai G, and Vee HF Jr (1999} Ca2+ independent myosin activation and contraction in chicken embryo fibroblasts. J. Physiol. 515:87-92
22. Elson El, Felder SF, Jay PV, Kolodney MS, and Pasternak C (1999} Forces in cell locomotion. Biochem. Soc. Symp., 65:299-314.
23. Kolodney MS and Elson El (1995} Contraction due to microtubule disruption is associated with increased phosphorylation of myosin regulatory light chain. Proc. Nat!. Acad. Sci. (USA} 92:10252-10256.
24. Kolodney MS and Elson El (1993} Correlation of myosin light chain phosphorylation with isometric contraction of fibroblasts. J. Bioi. Chem. 268:23850-23855.
25. Kolodney MS and Wysolmerski RB (1992} Isometric contraction of fibroblasts and endothelial cells: A quantitative study. J. Cell Bioi. 117:73-82.
26. lee RC and Kolodney MS (1987} Electrical injury mechanisms: Dynamics of the thermal response. Plast. Reconstr. Surg. 80:663-671.
27. lee RC and Kolodney MS (1987} Electrical injury mechanisms: Electrical breakdown of cell membranes. Plast. Reconstr. Surg. 80:672-679.
Honors and Awards
Outstanding leadership Award, "In Recognition of Exceptional leadership and Devoted Service to the Harbor UCLA Division of Dermatology" 2012
Victor D Newcomer Award, "Presented at the 55th Annual Meeting of Pacific Dermatologic Association" 2003
Victor Newcomer Teaching Award, "For Outstanding Teaching of UCLA Dermatology Residents" 2001, 2002, 2003
James Henry Yalem Prize in Dermatology, "For Outstanding Work in Dermatology by a Senior Medical Student" 1995
Spencer T. and Ann W. Olin Fellowship, "In Recognition of Superior Achievement in Biomedical Research" 1993
James Barret Brown Prize, "For Advancement of Knowledge in the Field of Plastic and Reconstructive Surgery" 1988
Professional & Scholarly Associations
Association of Professors of Dermatology 9/2006
Society for Investigative Dermatology 7/2000
American Academy of Dermatology 7/2000
Editor: Practical Reviews in Dermatology 1/2007-05/2011
Editorial Board: Procedural Dermatology 10/2015
About Michael Kolodney
Personal interests: Skiing; biking; poker
Michael S. Kolodney, M.D.-PhD, FAAD is Chairman of the Department of Dermatology at the West Virginia University (WVU) School of Medicine in Morgantown, West Virginia. In the School of Medicine at WVU, he holds an appointment as Professor of Dermatology.
Dr. Kolodney earned a Bachelor of Science (B.S.) degree in physics from MIT. He earned his MD-PhD degrees from Washington University School of Medicine in St. Louis,. Dr. Kolodney completed a combined residency in Dermatology and Internal Medicine at UCLA. He is board-certified in Dermatology by the American Board of Dermatology. He no longer maintains his board certification in Internal Medicine.
Dr. Kolodney was previously chief of Dermatology at Harbor-UCLA medical center and established a new Dermatology Residency Program there. He then became Chief of Dermatology at the Va Tech Carilion School of medicine and established a new Dermatology Residency Program there as well. He has previously served as the editor for Practical Reviews in dermatology. Dr. Kolodney has co-authored numerous peer-reviewed papers and has received honors and awards recognizing excellence in teaching and research. Of note, he developed a first in class drug to treat double chins that that has been FDA approved and is currently marketed by Allergan. His research is currently focused on translational approaches to imaging, genomics and therapy of skin diseases.
Grants and Research
Polynoma Inc. MAVIS trial - Seviprotimut-L Vaccine for Melanoma Recurrence $65,000 1/2015
Amgen Inc. $45,000 A Prospective Observational Study to Estimate the Proportion of Subjects with Plaque Psoriasis who Achieve Complete Clearance 5/2014
Amgen Inc. $600,000 AMAGINE-2 Trial (Anti IL-17 for Psoriasis) Role: P.l. for Carilion site 3/2013
Kythera Inc. Sponsored research agreement with to develop therapeutics targeting adipose tissue $1,700,000 Role: Principal Investigator 9/05-7/12
Kemia Inc. $10,000 Use of KC706 for the Treatment of Pemphigus Vulgaris Role: P.l. for Harbor-UCLA Site 1/01/2008
Dermatology Foundation $20,000 Program Development Grant Role: Principal Investigator 7/1/2006-6/30/2007
UCLA Center for Biological Radio-protectors $50,000 Mediators of radiation dermatitis Role: Principal Investigator 7/1/2006-6/30/2007
NIH 1-R41-HG003959-01 Fiber Optics Based Bioluminescence Imaging $107,000 Role: Principal Investigator 10/1/2005 - 10/1/2006
Genentech Raptiva RESPONSE Study $25,000 Role: Principal Investigator for Harbor site 9/1/2005-9/1/2007
LaBiomed Seed Grant 12076-01 MEK as a therapeutic target for B-raf mutated Melanomas $25,000 Role: Principal Investigator 1/1/2005-12/31/2006
Harbor-UCLA GCRC Effect of Topical Corticosteroids on Epidermal Adhesion Strength in Pemphigus Vulgaris $20,000 Role: Principal Investigator 7/1/2004-6/30/2005
Research Awards Program Prevention of Melanoma Metastasis through inhibition of RhoC isoprenylation $100,000 Role: Principal Investigator 7/1/2003-6/30/2005
Stein-Oppenheimer Research Award Effects of Braf inhibition on melanoma metastasis formation $20,000 Role: Principal Investigator 7/1/2003-6/30/2004
Melanoma Research foundation Inhibition of rhoC Prenylation by Statins $60,000 Role: Principal Investigator 7/1/2002-6/30/2004
Dermatology Foundation Career Development Award Mechanism of Spongiotic Change $110,000 Role: Principal Investigator 1/1/200-12/31/2002
Los Angeles Dermatology Foundation, Mechanism of Spongiotic Change $15,000 Role: Principal Investigator 1/1/2000-12/31/2001
Dermatology Foundation Mechanism of Spongiotic Change $10,000 Role: Principal Investigator 1/1/2000-12/31/2001
Patient Care Information
- Dermatology, American Board of Dermatology
Other Speciality Training, Intern in Internal Medicine
Brown University / Rhode Island Hospital, Providence, RI, 1996
Residency, Resident in Dermatology and Internal Medicine
UCLA School of Medicine, Los Angeles, CA, 1999
Fellowship, Research Fellow in Dermatology
UCLA School of Medicine, Los Angeles, CA, 2000